HOME >> BIOLOGY >> NEWS
Burnham Institute awarded $13 M for Program of Excellence in Nanotechnology

solutions to combat vulnerable plaque; 1) building delivery vehicles that can be used to transport drugs and nanodevices to sites of vulnerable plaque; 2) designing a series of self-assembling polymers that can be used as molecular nano-stents to physically stabilize vulnerable plaque, 3) creating nano-machines comprised of human proteins linked to synthetic nano-devices for the purpose of sensing and responding to vulnerable plaque.

"The Programs of Excellence in Nanotechnology is a vitally important research effort that will spur the development of novel technologies to diagnose and treat heart, lung, and blood diseases," said Elizabeth G. Nabel, M.D., director of the National, Heart, Lung and Blood Institute of the NIH. "The program brings together bioengineers, materials scientists, biologists, and physicians who will work in interdisciplinary teams. By taking advantage of the unique properties of materials at the nanoscale, these teams will devise creative solutions to medical problems."

PEN Director, Jeffrey Smith, Ph.D., Professor, The Burnham Institute, will oversee the Program's administrative and training components, as well as his own research component. Dr. Smith also directs the Center on Proteolytic Pathways at The Burnham Institute, recently established as one of first centers funded by the National Institute of Health's Roadmap Initiative. Erkki Ruoslahti, M.D., Ph.D., Distinguished Scientist and former President/CEO of The Burnham Institute, using in vivo phage display technology discovered in his laboratory, will identify and develop targeting elements needed to target the delivery of nanodevices to vulnerable plaque. Dr. Ruoslahti is credited with the first successful targeted delivery of a nanomachine into live tissue, using similar strategies. Also from The Burnham Institute are William B. Stallcup, Ph.D., Professor, who will supervise the and Francesca Marassi, Ph.D., Assistant Professor, who will provide NMR expertise for struc
'"/>

Contact: Nancy Beddingfield
nbeddingfield@burnham.org
858-646-3146
Burnham Institute
13-Jun-2005


Page: 1 2 3

Related biology news :

1. NIH awards $7.39 million to Burnham neurobiologists
2. CIRM awards $6M to Burnham Institute
3. CIRM awards $5.9 million to Burnham Institute
4. Burnham Institute for Medical Research announces affiliation with UC Santa Barbara
5. Burnham awarded $12.7 million from NIH to create one of nations top neuroscience research centers
6. Burnham Institute for Medical Research & UC San Diego establish Joint Center for Molecular Modeling
7. Burnham to collaborate on NCI-funded task force to find molecular signature for prostate cancer
8. Burnham Institute to collaborate in NCI funded Center of Cancer Nanotechnology Excellence
9. NFCR - Prostate Cancer Foundation unite with Burnham Institute to expedite cancer drug discovery
10. NIH selects Burnham Institute for Exploratory Center for Human Embryonic Stem Cell Research
11. Anthrax inhibitors identified by Burnham team

Post Your Comments:
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
(Date:12/17/2014)... 17, 2014 Achim Noack has been ... Stoller Group. In this position, Noack will assist Jerry ... matters, develop marketing strategy and supervise global marketing management ... “Achim has tremendous knowledge and experience in the crop ... “His experience and innovative thinking will be a great ...
(Date:12/17/2014)... Park, CA (PRWEB) December 17, 2014 ... announces today that it has entered into a ... Midland Company (ADM) to apply DNA2.0’s proprietary protein ... enzyme engineering process. , “We are extremely excited ... ProteinGPS engineering platform. This proprietary bioengineering technology ...
(Date:12/17/2014)... 17, 2014 Tigercat Pharma, Inc. today ... evaluating the investigational oral NK-1 receptor antagonist VPD-737 ... chronic itch who are unresponsive or inadequately responsive ... steroids and antihistamines. The primary ... Scale (VAS) itch score from baseline, comparing drug ...
(Date:12/15/2014)... -- GlassesOff Inc. (OTCBB: GLSO) announced today the appointment of ... of the Company,s Board of Directors. Mr. ... CEO until its acquisition by Stanley Black ... as the inventor of the first Wi-Fi-based Active RFID ... RFID solutions focused on improving operational efficiency, safety and ...
Breaking Biology Technology:Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3
Cached News: